Share your thoughts on our News & Insights section. Complete our survey to help us improve.

Share research

Next week on the stock market

What to expect from a selection of FTSE 100, FTSE 250 and selected other companies reporting week commencing 29 January 2024.

Important information - This article isn’t personal advice. If you’re not sure whether an investment is right for you please seek advice. If you choose to invest the value of your investment will rise and fall, so you could get back less than you put in.

  • Novo Nordisk - will investments in production lift the lid on 2024 growth guidance?

  • We’ll find out if fourth-quarter cash flows have clammed up for Shell

  • Diageo will be hoping to avoid any more earnings disappointments

What to expect from a selection of FTSE 100, FTSE 250 and selected other companies reporting next week.

Among those currently scheduled to release results next week:


No FTSE 350 Reporters



Full Year Results


Half Year Results


Q2 Results

Pets at Home*

Q3 Results


Full Year Results

SSP Group

Q1 Trading Statement


Full Year Results


Abrdn Private Equity Opportunities Trust

Full Year Results


Q4 Results

Novo Nordisk*

Full Year Results


3i Group

Q3 Operational Performance

3i Infrastructure

Q1 Trading Statement

AG Barr*

Full Year Trading Statement

Airtel Africa

Q3 Results


Full Year Results


Q1 Results


Q3 Trading Statement


Full Year Production Report


Q1 Trading Statement


Full Year Results


Full Year Results


Full Year Results



Full Year Results

*Events on which we will be updating investors.
Weekly Newsletter
Sign up for shares insight. Get our expert investment research direct to your inbox every week

Novo Nordisk

Novo Nordisk’s growth of late has been propelled by sales of its GLP-1 medicines in diabetes, with even stronger momentum in obesity care. We look forward to full year numbers next week, where the latest guidance suggests an increase of 32-38% for sales and 40-46% for operating profit.

The forthcoming results provide an opportunity for Novo to set initial guidance for 2024. We hope to hear how investments in manufacturing are relieving production bottlenecks. We’ll also be looking out for an update on the regulatory pathway for a once weekly insulin injection for diabetics, IcoSema, which has recently seen positive clinical trials data.

Prices delayed by at least 15 minutes


We’re not expecting to see a dip in oil & gas production in Shell’s fourth quarter numbers next week. However, lower refinery utilisation and weaker commodities prices have the potential to dent cash flows.

Volatile pricing is part and parcel of being an energy company. However, an increased commitment to shareholder distributions and significant investment plans in both traditional and renewable energy means that there’s growing competition for funds. Meanwhile, there’s been mounting pressure for Shell to double down on its renewable commitments. So, we’ll be keeping a close eye on Shell’s plans to allocate its cash in 2024.

Prices delayed by at least 15 minutes


Back in November 2023, Diageo shocked markets by warning that this year’s revenue and profit would both be lower than expected. This came as performance in its Latin America and Caribbean region was materially weaker than anticipated, with first-half organic sales set to decline by more than 20%. Because of this, first-half operating profit looks set to fall around 4.3% to £3.6bn when the group reports next week.

In the group’s other major regions, momentum is expected to remain positive, with sales rising across the board. The Guinness brewer has a strong portfolio of brands under its belt, which should help it to return to 5-7% organic sales growth over the medium term. We’ll be keeping a close eye on the demand picture, with any further weakness likely to bring this guidance into question.

Prices delayed by at least 15 minutes

Estimates are not a reliable indicator of future performance. Past performance is not a guide to the future. Investments rise and fall in value so investors could make a loss.

This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment. This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication. Non-independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place (including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing. Please see our full non-independent research disclosure for more information.

Weekly Newsletter
Sign up for Share Insight. Get our Share research team’s key takeaways from the week’s news and articles direct to your inbox every Friday.
Written by
Aarin Chiekrie
Aarin Chiekrie
Equity Analyst

Aarin is a member of the Equity Research team. Alongside our other analysts, he provides regular research and analysis on individual companies and wider sectors. Having a keen interest in global economics, he knows how macro-events can impact individual companies.

Our content review process
The aim of Hargreaves Lansdown's financial content review process is to ensure accuracy, clarity, and comprehensiveness of all published materials
Article history
Published: 26th January 2024